Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A
Children's Hospital, Boston, Massachusetts 02115.
J Am Acad Child Adolesc Psychiatry. 1993 Mar;32(2):350-3. doi: 10.1097/00004583-199303000-00016.
Clonidine has been suggested as an alternative pharmacotherapy for patients with attention-deficit hyperactivity disorder (ADHD) and comorbid tic disorders. To examine the efficacy of clonidine in this population of children, the use of clonidine in the treatment of children with ADHD with and without comorbid tic disorders was examined in a retrospective chart review of 54 children over a 4-year period.
Treatment was administered openly to these patients in a Pediatric Psychopharmacology Clinic, and response was assessed using clinical global improvement measures.
Clonidine treatment resulted in improvement in both the ADHD (39/54; 72%) and tic symptoms (18/24; 75%) groups. The findings suggested that the children with ADHD with comorbid tic disorders (23/24; 96%) have a more frequent positive behavioral response to clonidine than children with ADHD without comorbid tic disorders (16/30; 53%).
This report provides further support of a role for clonidine in the treatment of children with ADHD, particularly for those with comorbid tic disorders.
可乐定已被提议作为患有注意力缺陷多动障碍（ADHD）及共病抽动障碍患者的一种替代药物疗法。为研究可乐定在这类儿童群体中的疗效，我们对54名儿童在4年期间的病历进行回顾性分析，以考察可乐定在治疗患有或未患有共病抽动障碍的ADHD儿童中的应用情况。
在一家儿科精神药理学诊所对这些患者进行开放性治疗，并使用临床总体改善指标评估疗效。
可乐定治疗使ADHD组（39/54；72%）和抽动症状组（18/24；75%）均有改善。研究结果表明，患有共病抽动障碍的ADHD儿童（23/24；96%）对可乐定的积极行为反应比未患有共病抽动障碍的ADHD儿童（16/30；53%）更为频繁。
本报告进一步支持了可乐定在治疗ADHD儿童，尤其是患有共病抽动障碍儿童方面的作用。
